Hepatitis C

The analysis of NHANES data found individuals with viral hepatitis and NAFLD as well as lower income and no college education were at a greater risk of mortality.

The cross-sectional analysis found Medicaid nonexpansion status, fibrosis, and sobriety restrictions negatively impacted annual rates of DAA prescription fills.

An analysis of data from the NV-HOPE study calls attention to lower rates of HBV and HCV screening among low-income US veterans versus the general US veteran population.

Refusal of hospital-administered birth doses of the hepatitis B vaccine declined in Washington, DC, from 2017-2022 despite pandemic-related disruptions to other childhood vaccines.

Findings underscore the importance of HCC screening adherence in patients with HCV-related cirrhosis who achieve HCV cure for improving overall survival.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

This June 2024 month in review highlights hepatic pipeline developments, new MASH therapeutics on the road to FDA approval, and the latest installment of Qazi Corner.

The marketing authorization makes the Xpert HCV test and GeneXpert Xpress System the first point-of-care test for diagnosing HCV.

The network meta-analysis found tenofovir disoproxil fumarate was more likely to achieve virologic response at week 48, while entecavir was superior for 48-week biochemical response.

Despite missing the primary endpoint among the global study population, additional analyses of participants from the US revealed significant impacts on mortality reduction with larsucosterol.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.

8 weeks of treatment with combination bemnifosbuvir and ruzasvir showed a 97% SVR rate at 12 weeks post-treatment in a phase 2 lead-in cohort.

Phase 2b data show combination bulevirtide and peginterferon alfa-2a therapy resulted in greater percentages of undetectable HDV RNA versus bulevirtide alone.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on advances in the pathophysiology of hepatitis b virus for 2024.

HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.

Patients who missed their initial HCV treatment appointment had greater housing instability, transportation difficulty, and a history of medication non-adherence.

An analysis of FDA Adverse Event Reporting System data suggests baloxavir marboxil has lower hepatic toxicity than oseltamivir and may be a safer option for patients with liver diseases.

Results of the single-center study showed HCV treatment from PCPs decreased from 2015-2022 but must be improved to help reach elimination goals.

Results showed metabolic dysfunction was an independent predictor of liver-related events and hepatocellular carcinoma in patients with chronic HCV who achieved SVR.

Study results highlight the role of HCV and alcohol use in the growing global disease burden posed by cirrhosis, which is projected to increase over the next 20 years.

The CRL for the sBLA cites a lack of sufficient data to support the full evaluation of the effectiveness and safety of a 4-dose regimen in this patient population.

A novel score based on a combination of cytokeratins and routine laboratory tests provided a more accurate diagnosis of HCC versus serum α-fetoprotein alone.

Glecaprevir/pibrentasvir is an effective treatment for HCV with high rates of SVR, even in patients with cirrhosis undergoing a shorter treatment regimen.

This clinical quiz will test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America Hepatitis C guideline.

Results suggest chronic hepatitis B virus is globally underassessed and undertreated, especially among women and Asian minorities in the West.

Sofosbuvir/velpatasvir/voxilaprevir rescue therapy was safe and effective, and SVR did not significantly differ based on genotype, cirrhosis, or first-line therapy.

Findings suggest unstable housing may inhibit direct-acting antiviral treatment initiation in PWID with unstable housing compared to those with stable housing.

Vitamin D concentration was significant in chronic hepatitis B virus but not hepatitis C virus infection, suggesting its potential impact on immune response.

Results showed 46.45 and 72.74% increases in the global incidences of acute infection and HCV-related cirrhosis, respectively, in reproductive-age women.